A low‐molecular‐weight BRAF inhibitor, vemurafenib, has been shown to inhibit MAPK signalling, specifically in melanoma harbouring the BRAFV600E mutation, resulting in an antiproliferative action against malignant tumour cells in individuals diagnosed with cutaneous melanoma [2]. Here, BRAF is linked to melanoma.